Loading clinical trials...
Loading clinical trials...
Most participants with a relapsed or refractory non-Hodgkin's lymphoma that receive an autologous transplant are likely to suffer a relapse because standard myeloablative preparative regimens are unab...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Loyola University
NCT06090539 · Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
NCT04851119 · Colorectal Carcinoma, Endometrial Carcinoma, and more
NCT06484920 · Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, and more
NCT03938987 · Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, and more
Patrick Stiff, MD
Maywood, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions